Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 32, Number 6—June 2026

Research

Wickerhamomyces anomalus Fungemia during Healthcare-Associated Outbreak, Pereira, Colombia, 2025

Karen M. Ordoñez1, Diego H. Caceres1Comments to Author , Andres Ceballos-Garzon, Natalia Salazar-Giraldo, Bram Spruijtenburg, Lina M. Velasquez-Orozco, Eelco F.J. Meijer, Gabriel Vinazco, Elaine Cristina Francisco, Rodrigo Oliveira, Patricia Escandon, and Jacques F. Meis
Author affiliation: E.S.E. Hospital Universitario San Jorge de Pereira, Secretaría de Salud de Risaralda, Pereira, Colombia (K.M. Ordoñez, N. Salazar-Giraldo, L.M. Velasquez-Orozco, G. Vinazco); Immuno-Mycologics, Norman, Oklahoma, USA (D.H. Caceres); Universidad del Rosario, Bogota, Colombia (D.H. Caceres, A. Ceballos-Garzon); Radboudumc-CWZ Center of Expertise for Mycology, Nijmegen, the Netherlands (D.H. Caceres, B. Spruijtenburg, E.F.J. Meijer, J.F. Meis); Canisius-Wilhelmina Hospital (CWZ)/Dicoon, Nijmegen (B. Spruijtenburg, E.F.J. Meijer); Universidade Federal de São Paulo, São Paulo, Brazil (E. C. Francisco); Antimicrobial Resistance Institute of São Paulo, São Paulo (E. C. Francisco); Universidade Federal do Paraná, Curitiba, Brazil (E. C. Francisco, J.F. Meis); Bruker Daltonics GmbH & Co. KG, Bremen, Germany (R. Oliveira); Instituto Nacional de Salud, Bogotá (P. Escandon); University of Cologne, Cologne, Germany (J.F. Meis)

Main Article

Table 3

Summary of antimicrobial drugs used for patients with Wickerhamomyces anomalus fungemia during healthcare-associated outbreak, Pereira, Colombia, 2025

Antimicrobial drug Average duration No. (%) cases
Ampicillin and gentamicin 2–8 d 7 (70)
Amikacin 1–10 d 6 (60)
Vancomycin 2–26 d 6 (60)
Metronidazole 2–15 d 6 (60)
Oxacillin 2–8 d 4 (40)
Cefepime 3–36 d 4 (40)
Piperacillin/tazobactam 2–3 d 3 (30)
Meropenem 4–5 d 3 (30)
Ertapenem 4 d 2 (20)
Cefotaxime 6 d 2 (20)
Ampicillin/sulbactam 5 d 2 (20)
Caspofungin 14 d 10 (100)
Fluconazole* 6 d 1 (10)

*Switched from caspofungin.

Main Article

1These authors share first authorship for this article.

Page created: April 17, 2026
Page updated: June 01, 2026
Page reviewed: June 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external